Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Risankizumab New Formulation vs 90 mg/mL Formulation
NCT05283681Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 140 Days, Maximum observed serum concentration up to 113 Days and 6 more. Started Apr 2019; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05283681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283681.